← Leaderboards
Andrew S Huhn
Johns Hopkins University
$19,514,484
Attributed
$26,823,772
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,823,772 · 5
By mechanism
U01$17,459,984 · 2
UH3$3,632,165 · 1
R01$3,516,481 · 1
UG3$2,215,142 · 1
Top collaborators
- Kelly E Dunn3 shared
- Jill Alexandra Rabinowitz3 shared
- Patrick Finan2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Lawrence John Appel$45,566,796
- Kenneth Silverman$32,204,721
- Susan L Furth$36,670,372
- Lauren M Jansson$8,360,007
- Maxine L Stitzer$35,973,273
Others in their field
Other Emerging Leaders on “Craving”
- Andrew Walker · Emergent Product Development Gaithersbur$6,354,906
- Richard Joseph Johnson · Colorado Research Partners, Llc$6,102,731
- Mary F. Morrison · Temple Univ Of The Commonwealth$5,117,685
- Nikej Shah · Nirsum Laboratories, Inc.$4,866,388
- Hollis C Karoly · Colorado State University$4,536,169
- Cecilia Bergeria · Johns Hopkins University$4,120,012
Research focus
CravingDoseSleep DisturbancesSleeplessnessPublic HealthPersonsOpioidPharmaceutical PreparationsPolysomnographyOpioid Use DisorderTreatment OutcomeSleepEnrollmentPatient Self-ReportBuprenorphineActigraphyStressWristCommunitiesHydrocortisoneFda ApprovedImprovement On SleepDouble-Blind MethodPlacebos
Grant awards (10)
Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorder$6,029,705
U01 · FY2025 · DA · contact PI
Sleep and circadian rhythm phenotypes and mechanisms associated with opioid use disorder treatment outcomes$1,169,398
R01 · FY2025 · DA · contact PI
Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorder$6,175,490
U01 · FY2024 · DA · contact PI
Sleep and circadian rhythm phenotypes and mechanisms associated with opioid use disorder treatment outcomes$1,163,257
R01 · FY2024 · DA · contact PI
Evaluating the Role of the Orexin System in Circadian Rhythms of Sleep and Stress in Persons on Medication-Assisted Treatments for Opioid Use Disorder$623,135
U01 · FY2024 · HL · contact PI
Sleep and circadian rhythm phenotypes and mechanisms associated with opioid use disorder treatment outcomes$1,183,826
R01 · FY2023 · DA · contact PI
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder$3,632,165
UH3 · FY2021 · DA · contact PI
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder$1,076,067
UG3 · FY2020 · DA · contact PI
Evaluating the Role of the Orexin System in Circadian Rhythms of Sleep and Stress in Persons on Medication-Assisted Treatments for Opioid Use Disorder$4,631,654
U01 · FY2019 · HL · contact PI
Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder$1,139,075
UG3 · FY2019 · DA · contact PI